Publication Date
2-29-2024
Journal
Morbidity and Mortality Weekly Report
DOI
10.15585/mmwr.mm7308a3
PMID
38421935
PMCID
PMC10907036
PubMedCentral® Posted Date
2-29-2024
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
Adolescent, Adult, Humans, Child, Influenza Vaccines, Influenza, Human, Seasons, Case-Control Studies, Vaccine Efficacy
Abstract
In the United States, annual influenza vaccination is recommended for all persons aged ≥6 months. Using data from four vaccine effectiveness (VE) networks during the 2023-24 influenza season, interim influenza VE was estimated among patients aged ≥6 months with acute respiratory illness-associated medical encounters using a test-negative case-control study design. Among children and adolescents aged 6 months-17 years, VE against influenza-associated outpatient visits ranged from 59% to 67% and against influenza-associated hospitalization ranged from 52% to 61%. Among adults aged ≥18 years, VE against influenza-associated outpatient visits ranged from 33% to 49% and against hospitalization from 41% to 44%. VE against influenza A ranged from 46% to 59% for children and adolescents and from 27% to 46% for adults across settings. VE against influenza B ranged from 64% to 89% for pediatric patients in outpatient settings and from 60% to 78% for all adults across settings. These findings demonstrate that the 2023-24 seasonal influenza vaccine is effective at reducing the risk for medically attended influenza virus infection. CDC recommends that all persons aged ≥6 months who have not yet been vaccinated this season get vaccinated while influenza circulates locally.
Included in
Critical Care Commons, Influenza Humans Commons, Influenza Virus Vaccines Commons, Medical Sciences Commons, Pediatrics Commons